Halberd Cancer Therapeutics

Halberd Cancer Therapeutics is a wholly owned oncology-focused subsidiary of Halberd Corporation developing extracorporeal cancer treatments. The company's approach is based on removing or precisely controlling disease-associated antigens in bodily fluids using designed antibodies conjoined with proprietary nanoparticles and activated by laser emissive energy. Public disclosures describe preclinical, in-vitro work against several immuno-oncology related targets including PD-1, PD-L1, CTLA-4, interleukin-6, tumor necrosis factor alpha, and BTLA. The subsidiary appears to function primarily as a dedicated vehicle for Halberd's cancer research rather than as a fully independent operating biotech with disclosed clinical-stage assets.